New anti-cancer therapeutics require extensive in vivo characterization to identify endogenous 17 and exogenous factors affecting efficacy, to measure toxicity and mutagenicity, and to determine 18 genotypes resulting in therapeutic sensitivity or resistance. We used Caenorhabditis elegans as a 19 platform with which to characterize properties of anti-cancer therapeutic agents in vivo. We 20 generated a map of chemigenetic interactions between DNA damage response mutants and 21 common DNA damaging agents. We used this map to investigate the properties of the new anti-22 cancer therapeutic CX-5461. We phenocopied the photoreactivity observed in CX-5461 clinical 23 trials and found that CX-5461 generates reactive oxygen species when exposed to UVA 24 radiation. We demonstrated that CX-5461 is a mutator, resulting in both large copy number 25 variations and a high frequency of single nucleotide variations (SNVs). CX-5461-induced SNVs 26 exhibited a distinct mutational signature. Consistent with the wide range of CX-5461-induced 27 mutation types, we found that multiple repair pathways were needed for CX-5461 tolerance.
* To whom correspondence should be addressed. Tel:+1-604-822-8569 FAX: genotoxic agent with similarities to antineoplastic ellipticine and anthracycline-based anti-cancer 1 agents. A better understanding of CX-5461 can lead to more informed treatment approaches. 2 RESULTS 3 CX-5461 is a photosensitizer that generates ROS upon exposure to UVA 4 Photosensitivity is a common side-effect of many therapeutics [22] . Clinical trials evaluating 5 CX-5461 in patients with hematologic or advanced solid tumors reported cases of 6 photosensitivity [16, 17] . We used C. elegans as an in vivo model to investigate the 7 photosensitivity of CX-5461. We focused on the effect of UVA radiation on CX-5461 for several 8 reasons: 1) CX-5461 absorbs UVA and UVB radiation, 2) other quinolone-based molecules can 9 trigger photosensitivity upon UVA irradiation [22] , 3) UVA passes through clouds and glass, 10 accounting for more than 90% of the UV radiation reaching the Earth's surface, and 4) UVA 11 penetrates deep into the dermis and triggers chemical-induced photosensitivity. 12 13 First, we attempted to re-create the CX-5461-induced photosensitivity in wild-type C. elegans. 14 Young adult animals were exposed to CX-5461 for ~16 hours and then exposed to UVA 15 radiation. Photosensitivity was measured by assessing the viability of F1 progeny from exposed 16 animals. Wild-type animals were not sensitive to CX-5461 or UVA alone but were sensitive to 17 CX-5461 + UVA exposure ( Figure 1A) . Increasing either the concentration of CX-5461 or the 18 amount of UVA radiation enhanced the cytotoxicity in a dose dependent manner ( Figure 1A ). To 19 assess if the photosensitivity was limited to the germline, we assayed CX-5461 photosensitivity 20 in L1 larvae. Synchronized L1 larvae were arrested by starvation and treated with 100 µM CX-21 5461 for ~16 hours followed by exposure to 300 J/m 2 UVA radiation. Photosensitivity was 22 measured by assessing the developmental stage of the population after 96 hours. L1 wild-type 23 wild-type C. elegans to capture and characterize CX-5461-induced lethal mutations in the 1 presence and absence of UVA. The eT1 balancer is a reciprocal translocation of approximately 2 half of chromosome III and half of chromosome V and can capture both single nucleotide 3 variants (SNVs) and copy number variants (CNVs) in balanced regions, including terminal 4 deletion events and translocations [15] . 5 6 Exposure to CX-5461 or CX-5461 + UVA resulted in high frequencies of balanced lethal 7 mutations and dominant sterile F1 animals, which produced no progeny (Figure 2A ). Four 8 balanced recessive lethal mutations were recovered from a screen of 200 F1 progeny from 9 individuals treated with 100 µM CX-5461. UVA radiation increased the mutagenicity of CX-10 5461 more than four-fold. Nineteen balanced recessive lethal mutations were recovered from a 11 screen of 200 F1 progeny from individuals treated with 100 µM CX-5461 + 100 J/m 2 of UVA 12 radiation. 13 14 To elucidate the mutational signatures of CX-5461 and CX-5461 + UVA, we sequenced the 15 genomes of the 23 strains with eT1-balanced lethal mutations. The CX-5461-treated genomes 16 contained a range of mutation types, including large copy number variations (CNVs) and single 17 nucleotide variations (SNVs). First, we analyzed the mutations in the balanced regions to 18 identify the lesions responsible for the lethal phenotype. In the CX-5461 mutated strains, 9/23 19 contained large copy number variations in the balanced regions that could account for the 20 lethality (Table 1 ; Supplemental Figures 1-2) and 14/23 strains contained SNVs in essential 21 genes (Table 1) . 22
Analysis of CX-5461-induced CNVs 23
Most CX-5461-and CX-5461 + UVA-treated genomes contained at least one CNV. CNVs 1 ranged from simple deletions to complex events involving deletions, duplications, and 2 translocations (Supplemental Figure 1 and 2). The high frequency of CX-5461-induced CNVs 3 was consistent with the observation that DNA double strand break repair genes, such as the 4 homology-directed repair (HDR) gene brc-2 and the microhomology mediated end-joining 5 (MMEJ) gene polq-1, are required for CX-5461 tolerance in C. elegans [21] . CNV breakpoints 6 frequently contained regions of microhomology consistent with MMEJ (Table1; Figure 2B ). 7
Analysis of the regions surrounding the CNV breakpoints found DNA repeats (simple, tandem, 8 and inverted) flanking some of the breakpoints. 9
Analysis of CX-5461-induced SNVs 10
All CX-5461-exposed genomes contained a high frequency of heterozygous and homozygous 11
SNVs (Table 1 ). Genomes exposed to CX-5461 + UVA had more homozygous and heterozygous 12 SNVs in the balanced region compared to those exposed to CX-5461 alone ( Figure 2C ). The 13 increased frequency of SNVs in the CX-5461 + UVA treated genomes was consistent with the 14 increased frequency of balanced lethal mutations. 15 16 All 4,284 SNVs were included in the analysis because there were no obvious differences in the 17 characteristics of the mutational profiles of heterozygous or homozygous SNVs or between the 18 CX-5461 and CX-5461 + UVA-induced SNVs. The SNVs were distributed throughout the 19 genome with no bias for coding or non-coding regions ( Figure 2D Supplemental Table 1 ). 517 SNVs (12%) were present in 212 multi-21 nucleotide mutation (MNM) clusters consisting of 2-13 SNVs within a 1000 bp region. More 22 than 80% of the SNVs in MNMs were less than 15 bases from the neighboring mutations (Figure  23  2E ). It was possible that the SNVs were the product of repair or bypass of CX-5461-stabilized G-1 quadruplexes, so we searched 100 bases 5' and 3' of each SNV for G-quadruplex forming 2 structures using QuadBase2 webserver [28] . SNVs were not strongly correlated with G-3 quadruplex forming sequences. Only 0.75% of mutations flanking regions contained predicted 4 G-quadruplexes compared to 0.45% in a control set of EMS mutations from the Million 5
Mutation Project [29] . 6 7 CX-5461-induced SNVs exhibited a distinct mutational signature. Greater than 80% of the SNVs 8 were A to X changes with nearly 50% being A to T transversions ( Figure 2F ). To better 9 understand the mutagenicity of CX-5461, we used the pLogo, a probability Logo generator, to 10 examine the extended sequence context of the A to X mutations [30] . We observed changes in the 11 frequency of bases both 5' and 3' of the mutated adenine. Most notably, 70% of the bases 12 immediately 3' (+1 position) of the mutated adenine were thymine. Guanine was overrepresented 13 in the +2 position and cytosine was overrepresented in the -1 and -2 positions. In contrast, no 14 extended sequence context was detected flanking mutated guanine ( Figure 2G ). Although there 15 was a higher frequency of SNVs in the CX-5461 + UVA samples compared to CX-5461 16 genomes, we saw no difference in the types of SNVs suggesting that UVA exposure enhanced 17 the frequency of CX-5461-induced SNVs but did not change the mutational mechanism. 18
19
To identify sequence motifs that may be more prone to CX-5461 mutagenesis, we looked for 20 sites that were mutated in more than one line. Forty-seven sites were mutated in two or more 21 lines (127 SNVs). We analyzed 100 bases flanking each of the frequently-mutated sites for 22 sequences predicted to form secondary structures and found 25/47 flanking regions contained 23 inverted or tandem repeats (53%). For comparison, a similar analysis of 3,719 regions flanking 1 EMS-induced mutations from the Million Mutation Project [29] found 753 repeats (20.2%). 2 From this, it appears that CX-5461-induced mutations are more common in regions containing 3 tandem or inverted repeats. 4 5
CX-5461 intercalates into DNA 6
The broad distribution of CX-5461-induced mutations suggested that CX-5461 can affect DNA 7 even in the absence of G-quadruplex structures. Previous in silico analysis predicted that the 8 pharmacophore of CX-5461 can intercalate into a crystal structure of DNA (PDB code 1Z3F) 9
[31] in a manner similar to the antineoplastic agent ellipticine [32] . To test whether CX-5461 10 could intercalate into DNA, we incubated CX-5461 with a PCR-generated dsDNA and 11 visualized the migration of DNA on a 1% agarose gel with the dsDNA-specific dye SYBR-Safe. 12
Incubation of the dsDNA with CX-5461 resulted in a slower migrating DNA band suggesting 13 that intercalation had occurred ( Figure 3A ). The disruption of dsDNA was greater when the 14 DNA was denatured and reannealed in the presence of CX-5461. At higher concentrations, the 15 DNA-CX-5461 complex did not migrate into the gel ( Figure 3A) . 16 17 Intercalation of ellipticine into DNA results in partial unwinding and distortion of the DNA 18 duplex [31]. To determine whether CX-5461 intercalation distorted DNA structure and whether 19 G-quadruplex sequences were required, we incubated a PCR product predicted to form a G 20 quadruplex (G4) and a PCR product without a predicted G quadruplex (non-G4) with mung bean 21 nuclease (MBN), which cleaves single-stranded or distorted double-stranded DNA, for one hour 22 at the specified temperature and assessed the endonuclease activity on a 1% Syber-Safe 1 0 containing agarose gel. CX-5461 protected both G4 and non-G4 containing DNA fragments 1 from MBN activity relative to DNA without CX-5461 ( Figure 3B ). At 40 , both PCR products 2 without CX-5461 were degraded, whereas the samples containing CX-5461 were not degraded 3 suggesting that CX-5461 could increase the thermal stability of dsDNA. 4 5 Genotypic sensitivities to CX-5461 6
The high frequency of both SNVs and CNVs suggested that the DNA damage response to CX-7 5461 is complex. To further characterize the DNA damage response to CX-5461, we used an 8 acute exposure assay on a panel of 28 C. elegans DNA replication and repair mutants to generate 9 a genetic sensitivity profile for CX-5461. We then compared the CX-5461 sensitivity profile to 10 the profiles of the topoisomerase I poison camptothecin (CPT); the topoisomerase II poison 11 etoposide (ETP); the interstrand crosslinking (ICL) agent UVA-activated trimethyl psoralen 12 (UVA-TMP); and UV-C radiation (UV-C), which causes thymine dimers and photoproducts. 13 14 CX-5461 sensitivity was observed in 14 of the 28 DNA damage response mutants tested (Table  15 2). Mutations in genes implicated in replication stress (mus-81, smrc-1, helq-1, brd-1, atm-1, 16 polq-1, polz-1, polh-1, him-1) resulted in sensitivity to CX-5461. The CX-5461 sensitivity profile 17 was distinct from the other DNA damaging agents, sharing some but not all genotypic 18 sensitivities. Of the 14 CX-5461 sensitive strains, 11 were sensitive to UVA-TMP, 9 were 19 sensitive to UV-C, 8 were sensitive to CPT and 8 were sensitive to ETP. Given the overlapping 20 sensitivities of CX-5461 and UVA-TMP, it was surprising that the Fanconi Anemia pathway 21 mutants were not sensitive to CX-5461, demonstrating that CX-5461 does not result in ICLs. The 22 CX-5461 sensitivity profile has similarity to that of the topoisomerase poisons CPT and ETP 1 1 ( Figure 4A ). The main difference being that TLS and NER mutants were very sensitive to CX-1 5461 and not to either topoisomerase poison. 2 3 HDR and MMEJ are required for CX-5461 tolerance 4
Mutations affecting the different double strand break repair pathways caused differential 5 sensitivity to topoisomerase poisons and CX-5461. Non-homologous end joining (NHEJ) 6 mutants were not sensitive to topoisomerase poisons or CX-5461. HDR mutants (brd-1, rfs-1, 7
helq-1) were exquisitely sensitive to CPT but only mildly sensitive to ETP, whereas the MMEJ 8 mutant polq-1 was very sensitive to ETP but not sensitive to CPT. In contrast, mutations 9 affecting either HDR or MMEJ resulted in moderate sensitivity to CX-5461. To test whether 10 HDR and MMEJ were contributing independently to the repair of CX-5461 induced lesions, we 11 tested polq-1 brd-1, rfs-1 polq-1 and helq-1 polq-1 double mutants for increased sensitivity to 12 CX-5461. In all three cases, the double mutants exhibited increased CX-5461 sensitivity 13 suggesting that HDR and MMEJ contributed independently to the repair of CX-5461-induced 14 lesions ( Figure 4B ). 15 16
Replication arrested nucleotide excision repair mutants are sensitive to CX-5461 17
Nucleotide excision repair mutants xpa-1 and ercc-1 were sensitive to CX-5461. NER repairs 18 bulky single-stranded DNA lesions such as those formed by UV light and some cancer 19 chemotherapeutics. Most NER activity is transcription-coupled (TC-NER). It is possible to assay 20 the effect of DNA damaging agents on transcription-coupled repair by exploiting starvation-21 induced L1 diapause, in which replication is arrested. L1 larvae with TC-NER defects exposed to 22 transcription-blocking DNA damaging agents are unable to reinitiate development when released 23 from arrest [33], whereas, DNA damaging agents that do not block transcription reinitiate 1 development. To test whether CX-5461 caused transcription-blocking lesions, we assayed CX-2 5461 sensitivity in L1 arrested NER mutants. Replication-arrested L1 larvae were exposed to 3 CX-5461 + UVA, released from arrest, and their development stages were assessed 96 hours 4 later. CX-5461 + UVA-treated xpa-1 and ercc-1 L1 larvae failed to develop to later larval stages 5
suggesting that CX-5461 can cause transcription-blocking lesions ( Figure 4C ). In contrast, the 6 replication-associated CX-5461 hypersensitive mutant, mus-81 could reinitiate development after 7 L1 CX-5461 exposure and developed into sterile adults. These data demonstrate that CX-5461-8 induced lesions can block both transcription and replication. 9
10

TLS and NER mutants exacerbate CX-5461 photosensitivity 11
To test whether the CX-5461-induced photosensitivity was due, in part, to increased DNA 12 damage or changes in the nature of the DNA damage, we tested select mutants in the panel of C. 13 elegans DNA replication and repair mutants for increased photosensitivity. Most DNA repair 14 mutants were no more photosensitive to CX-5461 + UVA than wild-type animals ( Figure 4D ). 15 However, the translesion polymerase mutant polz-1 and the nucleotide excision repair mutant 16 xpa-1 exhibited greater embryonic death than expected. These results are consistent with the 17 observation that CX-5461 generates ROS after UVA exposure ( Figure 1E and 1F) and TLS and 18 NER are required for the repair of DNA damage induced by ROS generated by UVA exposure 19 [12] . 20
21
CX-5461 sensitive mutants and G-quadruplex stabilization 22
There are similarities between worms exposed to CX-5461 and worms lacking C. elegans 1 FANCJ ortholog, dog-1. CX-5461 can stabilize G-quadruplexes [21] and the loss of DOG-1 2 results in the formation and/or stabilization of G-quadruplex structures [27] . Furthermore, CX-3 5461-exposed animals and dog-1 mutants exhibit large and small chromosome rearrangements 4 that often have MMEJ-signatures at the breakpoints [11, 34] . To further investigate the 5 similarities between CX-5461 exposure and loss of dog-1, we tested whether loss of dog-1 6 resulted in negative genetic interactions with the CX-5461-sensitive mutants by measuring the 7 viability of dog-1 CX-5461-sensitive double mutants using a generational survival assay (Figure 8 5). The polq-1 mutant was very sensitive to loss of DOG-1 with fewer than 50% of the lines 9 surviving to the third generation. mus-81 and brd-1 mutants were also sensitive to dog-1-induced 10 G-quadruplex stabilization. However, not all CX-5461 sensitive mutants exhibited genetic 11 interaction with dog-1 as the loss of polz-1 did not affect the viability of dog-1 mutants. 12
13
DISCUSSION 14
Key to the development of new anti-cancer therapeutic agents is understanding their off-target 15 effects, mechanisms, and genotypic dependencies. While advances in target identification, 16 chemical synthesis, and in vitro analysis have led to improvements in drug development, less 17 progress has been made in improving toxicity and efficacy assays. The most common assay for 18 mutagenicity is the bacteria-based Ames test [35] , which has been used to assess the 19 mutagenicity, photomutagenicity, and phototoxicity of chemotherapeutics [36] . The efficacy of 20 the Ames test is limited because bacteria lack many of the genes responsible for the xenobiotic 21 metabolism of drugs, have different DNA damage repair pathways than eukaryotes, and it only 22 assays the reversion frequency of a single mutation. The small size, ease of handling, and 1 4 powerful genetic tools of C. elegans provide a sophisticated in vivo toxicity assay that combines 1 the technical advantages of a microorganism with greater biological complexity and a gene 2 complement more akin to human. Furthermore, the cytochrome P450-based metabolic 3 capabilities of C. elegans are broadly similar to those of mammals [37] . For these reasons, C. 4 elegans has been used as an in vivo model system to predict the effect of chemicals on 5 mammalian development [10], germline function [8, 9] , mutagenicity [13] and toxicity [38] . We 6 have used a complementary suite of mutagenicity, mutational profile, and genotypic sensitivity 7 assays that utilize C. elegans to characterize the new anticancer chemotherapeutic CX-5461. 8
Some anti-cancer drugs, such as vemurafenib, tamoxifen, and docetaxel, and many quinolone-9 based drugs can cause phototoxic reactions [22, 39] . CX-5461, which contains a quinolone 10 backbone, has resulted in photosensitivity in some patients [16, 17] . We were able to phenocopy 11 the photosensitivity in C. elegans and determine that the light sensitivity was accompanied by 12 reactive oxygen species-mediated phototoxicity. We demonstrate that C. elegans can be used as 13 an animal model to investigate drug-associated photosensitivity and test genetic and 14 environmental factors affecting photosensitivity and resistance. Given the strong ROS-mediated 15 phototoxicity and drug properties of CX-5461, CX-5461 may be useful for photodynamic 16 anticancer therapy, in which targeted light is used to activate a photosensitizer within cancer cells 17 leading to cell death. 18
C. elegans has proven to be an excellent model with which to investigate the mutagenicity and 19 mutational profiles of DNA damage response mutants or genotoxic compounds [11] [12] [13] . CX-20 5461 was mutagenic and the mutagenicity was increased by exposure to UVA light. The 21 recessive mutation frequencies for CX-5461 and CX-5461 + UVA were comparable to exposure to 5 mM and 25 mM Ethyl Methane Sulfonate (EMS), a common alkylating mutagen, or 1000 1 and 2500 rads gamma radiation [15] . suggests that CX-5461 does not cause DSBs directly but rather generates replication blocking 18 lesions, which in turn can lead to breaks. This is further supported by the observation that polq-1 19 and rfs-1 and other genes required for the tolerance of CX-5461, such as brd-1, smrc-1, and xpf-1 20 are also involved in the bypass or repair of replication blocking G-quadruplex structures that 21 form in dog-1 mutants [34,40-42] and are essential for the multigenerational survival of dog-1 22 mutants ( Figure 5 ). However, we observed very few G-quadruplex forming sequences in the 1 6 regions flanking SNVs or CNV breakpoints and we demonstrated that CX-5461 can intercalate 1 into non-G-quadruplex forming DNA sequences. Taken together, these data suggest that CX-2 5461 results in DNA lesions or structures that can stall or collapse replication forks leading to 3 DSBs even in the absence of G-quadruplexes. shifts we observed with DNA incubated with CX-5461. This distortion could make the ApT more 20 prone to TLS-mediated mutagenesis either directly or through secondary reactions with the 21 exposed adenine. Furthermore, both aristolochic acid and ellipticine can form covalent DNA 22 adducts after reductive activation by cytochromes P450. It is possible that CX-5461 forms In summary, C. elegans is a powerful platform with which to interrogate the in vivo biological 14
properties of both new and established anticancer therapeutic agents. The mutant panel we 15 assembled and queried with DNA damaging agents provides valuable information about the 16 types of damage generated by new DNA damaging therapeutics. From these data, we find that 17 CX-5461 is a multimodal anticancer agent with mechanistic similarities to ellipticines and 18 anthracyclines. This suggests that CX-5461 may be a more broadly applicable anticancer drug 19 with a therapeutic range beyond HDR-deficient tumours. 20
21
MATERIALS AND METHODS 22
1 8 were: atm-1(tm5027), brd-1(dw1), rfs-1(ok1372), cku-80(ok861), lig-4(ok716), hsr-9(ok759), 1 polq-1(tm2026), polh-1(lf31), polk-1(lf29), fcd-2 (tm1298), fan-1(tm423), fncm-1(tm3148), 2 msh-2(ok2410), ercc-1(tm1981), xpa-1(ok698), mus-81(tm1937), rcq-5(tm424), rtel-1(tm1866), 3 helq-1 (tm2134), dog-1(gk10), wrn-1(gk99), let-418(n3536), him-1(e879), hda-3(ok1991), 4 gld-1(op236), cep-1(gk138), dvc-1(ok260), smrc-1(gk176502), and polz-1(gk919715). Bristol 
Quantitative acute assay 17
Synchronized one-day-old adults were incubated in 100µM CX5461 (in NaH 2 PO 4 ) diluted in M9 18 buffer containing OP50, carbenicillin (50 µg/ml) and 1X nystatin for ~18 hours. Following 19 treatment, the animals were allowed to recover for 0.5 h on OP50 containing NGM plates before 20 1 9 and hatching larvae was counted one day later in order to calculate the percentage of embryo 1 survival after treatment. All results were from at least 30 treated animals (3 plates with 10 2 animals per plate). 3 4
The sensitivity score was calculated by normalizing the embryo survival rate under drug-treated 5 condition to non-drug condition with respect to that of wild-type N2 animals. 6
Mutagenesis screen for CX-5461 7
Strain BC2200 dpy-18/eT1(III);unc-46/eT1(V) was used in the mutagenesis screen. dpy-8 18/eT1(III);unc-46/eT1(V) animals were treated with or without 100µM CX-5461 for 18 hours 9 before UVA irradiation, and 200 single dpy-18/eT1(III);unc-46/eT1(V) F1s were picked in each 10 condition. Sterile phenotype at F1 is considered as acquiring a dominant lethal mutation, and 11 lines in which F2 or later generation that do not have Dpy Unc animals are counted as acquiring 12 a recessive lethal mutation on balanced regions of chromosome III or V. 13
Genome Sequencing 14
The lines that acquired recessive lethal mutations were maintained for at least three generations. 15
Worms were rinsed off with deionized water and concentrated. Genomic DNA was purified 16 using Puregene® Core Kit A (Qiagen). DNA-seq was performed at the Novogene 17 Bioinformatics Institute (Beijing, China). Sequence reads were mapped to the C. 18 elegans reference genome version WS230 (http://www.wormbase.org) using the short-read 19 aligner BWA [50], which resulted in an average sequencing depth for each sample ranging from 20 22x to 57x with a median of 34x. Single-nucleotide variants and small insertions/deletions were 21 identified and filtered with the help of the SAMtools toolbox [51] . Candidate variants at genomic 22 locations for which the parental N2 strain had an agreement rate with the reference genome 23 2 0 lower than 95% were eliminated from further consideration. Each variant was annotated with a 1 custom Perl script and gene information downloaded from WormBase version WS230. Copy 2 numbers were estimated from the alignments with a procedure analogous to that of Itani et al. 3
[52] using 5 kb wide overlapping sliding windows with the alignments from the parental strain 4 used as the reference. 5
CX-5461 agarose gel shift and mung bean endonuclease assays 6
To test whether CX-5461 could intercalate into DNA, we incubated CX-5461 for one hour at 7 room temperature with a PCR-generated dsDNA fragment and visualized the migration of DNA 8 on a 1% agarose gel containing the dsDNA-specific dye SYBR-Safe. To determine whether CX-9 5461 affected mung bean endonuclease activity, we incubated a PCR product predicted to form a 10 G quadruplex (G4) and a PCR product without a predicted G quadruplex (non-G4) with mung 11 bean nuclease (MBN), which cleaves single-stranded or distorted double-stranded DNA, for one 12 hour at the specified temperatures and assessed the endonuclease activity on a 1% Syber-Safe 13 containing agarose gel. 14
L1 exposure assay 15
Gravid animals were synchronized in the L1 stage by hypochlorite treatment (0.5M NaOH, 2% 16 hypochlorite). After overnight starvation, approximately 100 L1 larvae of each mutant strain 17 were incubated in 50 µl of M9 buffer containing OP50, carbenicillin (50 µg/ml), 1X nystatin, 18 500 µM NaH 2 PO 4 with and without 100 µM CX5461 for ~18 hours. Following treatment, worms 19 were allowed to recover for 0.5 h on OP50-containing NGM plates before they were irradiated 20 with the indicated amount of UVA exposure. Animals were imaged after 4 days following UVA 21 exposure with 20x using microscope.
1
Adult worms treated in 100µM CX-5461 for 18 hours were added with 25 µM 2',7'-1 dichlorodihydrofluorescein diacetate (H 2 DCFDA), and incubated for another hour in dark before 2 initial fluorescence measurement by Microplate reader. After initial measurement, worms were 3 irradiated with the indicated amount of UVA exposure, and then immediately sent for a second 4 measurement [24]. 5
Generational survival assay 6
Animals were plated individually and maintained at room temperature. Starting with 20 separate 7 lines at P 0 generation, a single L4 stage animal was transferred to a fresh plate at each generation. 8
A line was scored as unsustainable when the parent worm was either sterile or produced only 9 dead embryos. 10
Cell culture and treatment with CX5461 11 HCT116 and HT29 wild-type cells were obtained from American Type Culture Collection. Cells 12 were cultured in McCoy's 5A medium (Life Technologies) supplemented with 10% FBS at 37°C 13 and 5% CO 2 . CX5461 was purchased from Selleck Chemicals. Cells were seeded in 96-well 14 format (6 technical replicates) and after 24 hours, CX5461 (or DMSO) diluted in McCoy's 5A 15 medium was added to wells. 2 hours post incubation in the drug, cells were exposed to 50J/sqm 16 UVA and allowed to grow for 4 to 5 days. Cells were fixed in 3.7% paraformaldehyde and 17 stained with Hoechst 33342 before nuclei were counted on Cellomics Arrayscan VTI. 18
Yeast assays 19
Wild-type (BY4742) and rad52Δ yeast strains were diluted from mid-log phase to OD 600 =0.01 in 20
200µl SC media +/-CX-5461 in 96-well plates. Cells were incubated for 3 hours +/-CX-5461 21 with constant shaking before UVA treatment and subsequent loading to a TECAN M200 plate 22 reader. OD 600 readings were measured every 30 minutes over a period of 24 hours and plates 23 The large animals are the treated P0 individuals. C. HCT116 and HT29 colorectal cancer cell 9 lines were treated with increasing concentrations of CX-5461 and exposed to UVA irradiation in 10 96-well format and cell nuclei counted after 96 hours. Student's t-test ****, P< 0.0005; ******, 11 P<0.000005. D. Growth curve analysis of the relative fitness of wild-type and rad52 yeast 12 developed into sterile adults, whereas xpa-1 mutants arrested in L1. D. Differential sensitivity of 17 worm mutants upon exposure to CX-5461 + UVA. CX-5461 hypersensitive mutants were tested 18 at low [CX-5461] (Right). Note that xpa-1 and polz-1 are the only mutants that are more 19 sensitive to CX-5461+UVA when normalized to account for the sensitivity to CX-5461 alone. 20 Note the higher frequency of on the balanced chromosomes III and V. 7 Supplementary Table 1 . Right-constant UVA dose. B. Representative images of WT C. elegans populations 96 hours after CX-5461 +UVA exposure of synchronized WT L1 larvae. The large animals are the treated P0 individuals. C. HCT116 and HT29 colorectal cancer cell lines were treated with increasing concentrations of CX-5461 and exposed to UVA irradiation in 96-well format and cell nuclei counted after 96 hours. Student's t-test ****, P< 0.0005; ******, P<0.000005. D. Growth curve analysis of the relative fitness of wild-type and rad52 yeast exposed to CX-5461 + UVA radiation. Figure 4 . Genotypic sensitivity to CX-5461. A. Genotypic sensitivity profile of CX-5461. Venn diagram shows that the CX-5461-sensitive mutants also exhibited sensitivity to other DNA-damaging agents, including the topoisomerase poisons camptothecin (CPT), and etoposide (ETP). B. Loss of polq-1 sensitizes HDR-associated mutants (brd-1, rfs-1, and helq-1) to CX-5461. The bar graph showed the embryo survival rate for adult animals treated with the indicated dose of CX-5461. Student's t-test *, P<0.05 **, P<0.005, *** P<0.0005 C. UVA enhances the toxicity of CX-5461. The image shows the growth and development of worms four days after L1 larva-treatment. Upon CX-5461 treatment and UVA irradiation, mus-81 mutants developed in sterile adults, whereas xpa-1 mutants were arrested in L1. D. Differential sensitivity of worm mutants upon exposure to CX-5461 + UVA. CX-5461 hypersensitive mutants were tested at low [CX-5461] (Right). Note that xpa-1 and polz-1 are the only mutants that are more sensitive to CX-5461+UVA when normalized to account for the sensitivity to CX-5461 alone. Figure 5 . Effect of G-quadruplex stabilization on CX-5461-sensitive mutants. Multigenerational fitness assay. Loss of polq-1, mus-81 or brd-1 reduced the fitness of dog-1 mutants.
